1-[1-[2-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]acetyl]piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-one | 1219921-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 1-[1-[2-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]acetyl]piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-one
• CAS: 1219921-58-0
• 化学式: C₂₁H₁₉ClN₆O₃
• 分子量: 438.873
• InChiKey: RAHHKSHSCHFSMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1,3-二氢-1-(4-哌啶基)-2H-咪唑并[4,5-b]吡啶-2-酮 、 (5-(2-chlorophenyl)-[1,3,4]oxadiazol-2-yl)acetic acid 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-[1-[2-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]acetyl]piperidin-4-yl]-3H-imidazo[4,5-b]pyridin-2-one
  参考文献：
  名称：

  Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine

  摘要：

  A pharmacophore model was built, based on known CGRP receptor antagonists, and this was used to aid the identification of novel leads. Analogues were designed, modelled and synthesised which incorporated alternative `LHS' fragments linked via either an amide or urea to a privileged `RHS' fragment commonly found in CGRP receptor antagonists. As a result a novel series of oxadiazole CGRP receptor antagonists has been identified and the subsequent optimisation to enhance both potency and bioavailability is presented. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.012

文献信息

• Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine
  作者：Paula L. Nichols、Jonathan Brand、Michael Briggs、Mathilde D’Angeli、Jennifer Farge、Stephen L. Garland、Paul Goldsmith、Rio Hutchings、Ian Kilford、Ho Y. Li、David MacPherson、Fiona Nimmo、Francis Dominic Sanderson、Sanjeet Sehmi、Nicola Shuker、John Skidmore、Michael Stott、Jennifer Sweeting、Hasmi Tajuddin、Andrew K. Takle、Giancarlo Trani、Ian D. Wall、Robert Ward、David M. Wilson、David Witty

  DOI：10.1016/j.bmcl.2010.01.012

  日期：2010.2

  A pharmacophore model was built, based on known CGRP receptor antagonists, and this was used to aid the identification of novel leads. Analogues were designed, modelled and synthesised which incorporated alternative `LHS' fragments linked via either an amide or urea to a privileged `RHS' fragment commonly found in CGRP receptor antagonists. As a result a novel series of oxadiazole CGRP receptor antagonists has been identified and the subsequent optimisation to enhance both potency and bioavailability is presented. (C) 2010 Elsevier Ltd. All rights reserved.